SCHEMBL1543343

SCHEMBL1543343

COc1c(C=Cc2ccccn2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
IP6K1 Q92551 1/20 0.36
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
NFE2L2 Q16236 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TNFRSF1A P19438 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
ATM Q13315 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
GSK3B P49841 1/20 0.32
ADRA2A P08913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543341 1.00 CYP3A4 (0.61) CYP3A4NPC1RAB9AKDM4EGAA
SCHEMBL1764331 0.85 CYP3A4 (0.74) CYP3A4EGFRERBB2NFE2L2TNFRSF1A
SCHEMBL1764330 0.85 CYP3A4 (0.74) CYP3A4EGFRERBB2NFE2L2TNFRSF1A
SCHEMBL1542798 0.85 CYP3A4 (0.70) CYP3A4NPC1RAB9AKDM4EMAPT
SCHEMBL1542800 0.85 CYP3A4 (0.70) CYP3A4NPC1RAB9AKDM4EMAPT
SCHEMBL12678795 0.84 CYP3A4 (0.66) CYP3A4NPC1RAB9AEGFRERBB2
SCHEMBL1542386 0.84 CYP3A4 (0.64) CYP3A4NPC1RAB9AEGFRERBB2
SCHEMBL1542383 0.84 CYP3A4 (0.64) CYP3A4NPC1RAB9AEGFRERBB2
SCHEMBL1543150 0.83 CYP3A4 (0.59) CYP3A4EGFRERBB2
SCHEMBL1543153 0.83 CYP3A4 (0.59) CYP3A4EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885NPC1 972/4885RAB9A 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.